|
1
|
Saif MW, Sviglin H and Carpenter M: Impact
of ethnicity on outcome in pancreatic carcinoma. JOP. 6:246–254.
2005.PubMed/NCBI
|
|
2
|
Rodriguez JA, Li M, Yao Q, Chen C and
Fisher WE: Gene overexpression in pancreatic adenocarcinoma:
diagnostic and therapeutic implications. World J Surg. 29:297–305.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kawasaki H, Toyoda M, Shinohara H, et al:
Expression of survivin correlates with apoptosis, proliferation and
angiogenesis during human colorectal tumorigenesis. Cancer.
91:2026–2032. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ikeda N, Nakajima Y, Sho M, et al: The
association of K-ras gene mutation and vascular endothelial growth
factor gene expression in pancreatic carcinoma. Cancer. 92:488–499.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Satoh K, Kaneko K, Hirota M, Masamune A,
Satoh A and Shimosegawa T: Expression of survivin is correlated
with cancer cell apoptosis and is involved in the development of
human pancreatic duct cell tumors. Cancer. 92:271–278. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee MA, Park GS, Lee HJ, et al: Survivin
expression and its clinical significance in pancreatic cancer. BMC
Cancer. 5:1272005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Itakura J, Ishiwata T, Friess H, et al:
Enhanced expression of vascular endothelial growth factor in human
pancreatic cancer correlates with local disease progression. Clin
Cancer Res. 3:1309–1316. 1997.
|
|
8
|
Ikeda N, Adachi M, Taki T, et al:
Prognostic significance of angiogenesis in human pancreatic cancer.
Br J Cancer. 79:1553–1563. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Olie RA, Simoes-Wust AP, Baumann B, et al:
A novel antisense oligonucleotide targeting survivin expression
induces apoptosis and sensitizes lung cancer cells to chemotherapy.
Cancer Res. 60:2805–2809. 2000.
|
|
10
|
Ciardiello F, Bianco R, Damiano V, et al:
Antiangiogenic and antitumor activity of anti-epidermal growth
factor receptor C225 monoclonal antibody in combination with
vascular endothelial growth factor antisense oligonucleotide in
human GEO colon cancer cells. Clin Cancer Res. 6:3739–3747.
2000.
|
|
11
|
Yonesaka K, Tamura K, Kurata T, et al:
Small interfering RNA targeting survivin sensitizes lung cancer
cell with mutant p53 to adriamycin. Int J Cancer. 118:812–820.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dvorak HF, Nagy JA, Feng D, Brown LF and
Dvorak AM: Vascular permeability factor/vascular endothelial growth
factor and the significance of microvascular hyperpermeability in
angiogenesis. Curr Top Microbiol Immunol. 237:97–132. 1999.
|
|
14
|
Jones A and Fujiyama C: Angiogenesis in
urological malignancy: prognostic indicator and therapeutic target.
BJU Int. 83:535–555. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hayashibara T, Yamada Y, Miyanishi T, et
al: Vascular endothelial growth factor and cellular chemotaxis: a
possible autocrine pathway in adult T-cell leukemia cell invasion.
Clin Cancer Res. 7:2719–2726. 2001.PubMed/NCBI
|
|
16
|
Xie K, Wei D and Huang S: Transcriptional
anti-angiogenesis therapy of human pancreatic cancer. Cytokine
Growth Factor Rev. 17:147–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang C, Tan T, Yi XP, Shen H and Li YX:
Lentivirus-mediated shRNA targeting XIAP and survivin inhibit
SW1990 pancreatic cancer cell proliferation in vitro and in vivo.
Mol Med Rep. 4:667–674. 2011.PubMed/NCBI
|
|
18
|
O’Connor DS, Schechner JS, Adida C, et al:
Control of apoptosis during angiogenesis by survivin expression in
endothelial cells. Am J Pathol. 156:393–398. 2000.
|
|
19
|
Mesri M, Morales-Ruiz M, Ackermann EJ, et
al: Suppression of vascular endothelial growth factor-mediated
endothelial cell protection by survivin targeting. Am J Pathol.
158:1757–1765. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S
and Muramatsu T: A small interfering RNA targeting vascular
endothelial growth factor as cancer therapeutics. Cancer Res.
64:3365–3370. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Forster Y, Meye A, Krause S and Schwenzer
B: Antisense-mediated VEGF suppression in bladder and breast cancer
cells. Cancer Lett. 212:95–103. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meister G, Landthaler M, Dorsett Y and
Tuschl T: Sequence-specific inhibition of microRNA- and
siRNA-induced RNA silencing. RNA. 10:544–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
